HC Wainwright Forecasts Lower Earnings for Legend Biotech

Legend Biotech Co. (NASDAQ:LEGN - Free Report) - Equities researchers at HC Wainwright decreased their Q4 2025 earnings per share (EPS) estimates for shares of Legend Biotech in a note issued to investors on Wednesday, April 16th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn $0.10 per share for the quarter, down from their previous estimate of $0.11. HC Wainwright currently has a "Buy" rating and a $75.00 target price on the stock. The consensus estimate for Legend Biotech's current full-year earnings is ($1.31) per share.

Legend Biotech (NASDAQ:LEGN - Get Free Report) last posted its earnings results on Tuesday, March 11th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.46. The business had revenue of $186.50 million for the quarter, compared to analyst estimates of $179.00 million. Legend Biotech had a negative net margin of 66.92% and a negative return on equity of 29.69%. The firm's quarterly revenue was up 134.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.40) EPS.

Several other brokerages have also issued reports on LEGN. Morgan Stanley cut their price target on Legend Biotech from $82.00 to $80.00 and set an "overweight" rating on the stock in a research note on Monday, March 17th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $84.00 target price on shares of Legend Biotech in a report on Tuesday. Piper Sandler restated an "overweight" rating and issued a $78.00 price target on shares of Legend Biotech in a research report on Monday, December 30th. Finally, Guggenheim reiterated a "neutral" rating on shares of Legend Biotech in a report on Wednesday, March 12th. One research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $78.82.

Legend Biotech Price Performance

Shares of Legend Biotech stock traded up $1.73 during midday trading on Thursday, reaching $33.97. The company had a trading volume of 433,496 shares, compared to its average volume of 1,234,764. The stock has a fifty day simple moving average of $34.96 and a 200 day simple moving average of $37.53. Legend Biotech has a 1-year low of $29.27 and a 1-year high of $60.87. The company has a current ratio of 4.98, a quick ratio of 4.90 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $6.24 billion, a price-to-earnings ratio of -35.97 and a beta of 0.21.

Institutional Investors Weigh In On Legend Biotech

Several hedge funds have recently bought and sold shares of the stock. State Street Corp grew its holdings in Legend Biotech by 0.4% in the 3rd quarter. State Street Corp now owns 1,140,222 shares of the company's stock valued at $55,563,000 after buying an additional 4,735 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new stake in Legend Biotech in the 3rd quarter worth about $229,000. Geode Capital Management LLC grew its position in shares of Legend Biotech by 3.6% during the 3rd quarter. Geode Capital Management LLC now owns 494,864 shares of the company's stock worth $23,933,000 after purchasing an additional 17,337 shares in the last quarter. Franklin Resources Inc. bought a new position in shares of Legend Biotech during the third quarter worth approximately $12,837,000. Finally, Exome Asset Management LLC acquired a new stake in shares of Legend Biotech in the third quarter valued at approximately $2,290,000. 70.89% of the stock is currently owned by institutional investors and hedge funds.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).